Thanks. Okay so they had $3m in cash and established a $2m standby credit facility 'just in case' which they may not need to use, until the R&D & other receivables of $6m are banked.
So effectively as at 30 June 2023 they have $9m of their own cash plus a $2m line of credit which may not cost them anything if they choose not to use it.
I can see potential for a deep pocketed partner stepping up to fund the development and future trials of CRO-67 and so probably no immediate need to raise funds, although they may choose to do anyway.
I have now changed my position (which I forgot to do previously) as sadly I recently sold out of my holdings at a massive loss but wish existing holders the best of luck all the same.
- Forums
- ASX - By Stock
- NOX
- Ann: US FDA grants Orphan Drug Designation for CRO-67
Ann: US FDA grants Orphan Drug Designation for CRO-67, page-61
-
- There are more pages in this discussion • 4 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add NOX (ASX) to my watchlist
(20min delay)
|
|||||
Last
9.8¢ |
Change
-0.017(14.8%) |
Mkt cap ! $28.63M |
Open | High | Low | Value | Volume |
11.5¢ | 11.5¢ | 9.8¢ | $70.79K | 680.9K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
1 | 25356 | 9.8¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
10.0¢ | 240399 | 1 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
1 | 25356 | 0.098 |
2 | 176978 | 0.096 |
1 | 35000 | 0.094 |
1 | 99321 | 0.090 |
2 | 112500 | 0.080 |
Price($) | Vol. | No. |
---|---|---|
0.115 | 300000 | 1 |
0.120 | 537272 | 3 |
0.125 | 128094 | 1 |
0.130 | 249671 | 5 |
0.135 | 399760 | 2 |
Last trade - 16.10pm 13/09/2024 (20 minute delay) ? |
Featured News
NOX (ASX) Chart |
The Watchlist
LPM
LITHIUM PLUS MINERALS LTD.
Simon Kidston, Non--Executive Director
Simon Kidston
Non--Executive Director
SPONSORED BY The Market Online